

# Heart Failure




ACS AF/SPAF CKD Dys/Ath NAFL/NASH **HF** Obesity PAD PH T1D T2D VT



**Martha Klovstad, Ph.D.**  
Therapy Area Director,  
Heart Failure

Martha received her doctorate in Molecular Biology from Princeton University and completed postdoctoral training at Stanford University. She is an experienced analyst with broad scientific and therapeutic expertise and strong analytical capabilities and leads CVrg's heart failure team.



**Aubrey Ledford, Ph.D.**  
Disease Area Manager

Aubrey received her Ph.D. in Molecular and Cellular Pathobiology from Wake Forest University.

She brings over 10 years of pharmaceutical industry experience to CVrg including pipeline and clinical trial analysis, in-depth KOL research, conference analysis, translational research, and direct support of clinical trials. Her experience reaches all phases of product development, enabling her to understand the needs and priorities of CVrg clients.



## CVrg Market Strategies™ report

**Heart Failure, 2018–2027** is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment, and market forecasts. KOL comments, SWOTs, clinical trial tracking, estimations of launch dates, and target patient populations are included for products  $\geq$  Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in Heart Failure from CVrg Sentinel, Conference, Insights, and Advisory research are also included.

## CVrg Sentinel™ monthly updates

CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of HF assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.

## CVrg Conference™ expert coverage

CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC, and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what's new, what's important, and why.

## CVrg KOL Insights™ primary research

CVrg experts conduct primary research with KOLs in Heart Failure, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our "omnibus" discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today.

## CVrg Advisory™ answers to your ad-hoc inquiries

CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in heart failure drug and device markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.